Loading...
XSHE
002252
Market cap6.37bUSD
Jul 11, Last price  
6.92CNY
1D
-0.29%
1Q
0.73%
Jan 2017
-70.03%
IPO
11.08%
Name

Shanghai RAAS Blood Products Co Ltd

Chart & Performance

D1W1MN
P/E
25.64
P/S
5.73
EPS
0.27
Div Yield, %
0.97%
Shrs. gr., 5y
6.12%
Rev. gr., 5y
34.58%
Revenues
7.96b
+21.27%
303,192,604278,689,993309,976,913309,860,472387,519,941483,357,124567,385,772662,676,897496,359,5581,319,735,2302,013,321,6292,326,250,3481,927,748,4251,804,235,3992,584,983,9822,761,682,0364,287,726,7496,567,198,5817,963,958,566
Net income
1.78b
-5.35%
51,242,49750,711,18081,769,205104,790,807135,663,016185,498,269200,354,617225,013,842143,794,617510,854,9401,442,414,3011,613,153,629835,828,5880607,893,7111,323,711,0551,294,510,0501,880,090,0661,779,476,930
CFO
2.28b
+32.01%
54,016,44753,584,846175,710,568107,642,052116,011,121200,209,539178,028,545263,464,6880465,961,164762,420,968638,223,427264,949,553262,500,811872,694,4701,168,847,1461,294,013,2191,725,596,0632,277,884,080
Dividend
Sep 30, 20240.037 CNY/sh

Profile

Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex concentrate, human fibrinogen, human thrombin and human fibrin sealant, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. It also provides testing services for blood products, vaccines, diagnostic reagents, and testing equipment. The company also exports its products to Southeast Asia and Latin America. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is based in Shanghai, China.
URL
http://www.raas-corp.com
IPO date
Jun 23, 2008
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
7,963,959
21.27%
6,567,199
53.16%
Cost of revenue
5,621,456
4,276,064
Unusual Expense (Income)
NOPBT
2,342,503
2,291,135
NOPBT Margin
29.41%
34.89%
Operating Taxes
426,651
400,610
Tax Rate
18.21%
17.49%
NOPAT
1,915,851
1,890,525
Net income
1,779,477
-5.35%
1,880,090
45.24%
Dividends
(188,742)
Dividend yield
0.44%
Proceeds from repurchase of equity
(999,995)
BB yield
1.90%
Debt
Debt current
1,976
Long-term debt
2,988
3,693
Deferred revenue
9,492
12,769
Other long-term liabilities
7,059
Net debt
(20,372,297)
(18,905,183)
Cash flow
Cash from operating activities
2,277,884
1,725,596
CAPEX
(450,797)
Cash from investing activities
(670,594)
Cash from financing activities
(1,091,090)
FCF
2,053,527
1,856,754
Balance
Cash
4,198,311
4,215,192
Long term investments
16,176,975
14,695,659
Excess cash
19,977,087
18,582,491
Stockholders' equity
14,980,265
14,269,697
Invested Capital
14,687,592
14,432,422
ROIC
13.16%
13.36%
ROCE
7.89%
7.98%
EV
Common stock shares outstanding
6,590,655
6,740,788
Price
8.00
26.18%
6.34
-7.04%
Market cap
52,725,242
23.37%
42,736,595
-7.04%
EV
32,368,807
23,831,413
EBITDA
2,514,560
2,475,664
EV/EBITDA
12.87
9.63
Interest
458
263
Interest/NOPBT
0.02%
0.01%